Endocrinology and Metabolism

Original Articles

Efficacy and Safety of Stage 5 Connected Insulin Pens in Type 1 or Type 2 Diabetes: Randomized Controlled Trial Protocol: Ji Yoon Kim, Nam Hoon Kim, Soo Heon Kwak, Chang Hee Jung, Eun Seok Kang, Jun Sung Moon, Sun Joon Moon, So Yoon Kwon, Jee Hee Yoo, Younghoon Kim, Tae-min Lee, Chung-il Yang, Jae Hyeon Kim, Sang-Man Jin; Received July 26, 2025 Accepted October 13, 2025 Published online December 12, 2025; DOI: https://doi.org/10.3803/EnM.2025.2579 [Epub ahead of print]

1,251 View
49 Download

Abstract PDF PubReader ePub: Background
Stage 2 or 3 connected insulin pens (CIPs) refer to tracking insulin pens that are capable of transmitting insulin dose data via cloud connectivity. Stage 4 CIPs feature a bolus calculator that determines appropriate insulin doses based on real-time continuous glucose monitoring (CGM) data, carbohydrate intake, previous dosing history, and preset parameters. Stage 5 CIPs additionally offer advanced decision-support features, such as education modules and coaching. However, the efficacy and safety of Stage 5 CIPs have not yet been established.
Methods
In this prospective, open-label, parallel-group, multicenter, randomized controlled trial, we will include adults aged ≥19 and <75 years with type 1 or type 2 diabetes receiving multiple daily insulin injections (MDI) and having glycosylated hemoglobin (HbA1c) levels of 7.5% to 12.0%. In total, 152 participants will be randomized in a 1:1 ratio to receive either Stage 5 CIPs with CGM or tracking insulin pens with CGM. Stage 5 CIPs include a Setup Wizard that recommends individualized initial settings and an algorithm that provides advanced insulin dosing guidance based on analyses of each participant’s CGM and insulin injection data. The primary outcome will be the change in HbA1c levels from baseline to week 12 (ClinicalTrials.gov, NCT07004153).
Conclusion
This trial will determine whether Stage 5 CIPs are superior to tracking insulin pens in improving glycemic control among adults with type 1 or type 2 diabetes treated with MDI. Overall, this study may offer a promising strategy for enhancing the management and outcomes of patients with diabetes.

Diabetes, obesity and metabolism
Distinct Pituitary-Adrenal Responses to Hypoglycemia in Type 1 and Type 2 Diabetes: Yun Hu, Reng-na Yan, Ting-ting Cai, Xiao-wei Zhu, Jian-hua Ma, Bo Ding; Endocrinol Metab. 2026;41(1):162-173. Published online December 3, 2025; DOI: https://doi.org/10.3803/EnM.2025.2479

938 View
49 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Hypoglycemia remains a major barrier to optimal glycemic control in diabetes. Counter-regulatory hormonal responses, particularly those involving the pituitary and adrenal systems, play a central role in mitigating hypoglycemia, yet differences between diabetes subtypes are not well characterized. We aimed to investigate pituitary-target gland responses to hypoglycemia in patients with type 2 diabetes mellitus (T2DM) and type 1 diabetes mellitus (T1DM).
Methods
We enrolled drug-naive patients with newly diagnosed T2DM or T1DM, along with controls who did not have diabetes. Participants with diabetes received insulin pump therapy until normoglycemia was achieved. Hyperinsulinemic euglycemic-hypoglycemic clamps were then performed in all participants. Hormonal profiles of the pituitary-adrenal axis and C-peptide were serially measured during the clamps.
Results
During hypoglycemic clamps, C-peptide, thyroid-stimulating hormone, estradiol, and testosterone decreased, whereas prolactin, adrenocorticotropic hormone (ACTH), cortisol, and growth hormone (GH) increased significantly according to repeatedmeasures analysis of variance (ANOVA) (P<0.05 for all). Compared to controls and T2DM, patients with T1DM exhibited elevated basal GH (P=0.002) and an exaggerated GH response to hypoglycemia (P=0.002), with earlier onset and sustained elevation. In contrast, patients with T2DM showed higher ACTH (P=0.024) and cortisol (P=0.043) levels during hypoglycemia compared to controls and T1DM. Relative to the T1DM group, the T2DM group demonstrated lower testosterone and higher estradiol levels during hypoglycemia (P<0.001 for both).
Conclusion
Distinct diabetes subtypes demonstrate divergent pituitary-adrenal counter-regulatory responses to hypoglycemia, suggesting unique pathogenic mechanisms contributing to glycemic variability. The exaggerated GH response in T1DM may aggravate glucose fluctuations, whereas elevated ACTH and cortisol in T2DM could perpetuate insulin resistance.

Review Articles

Diabetes, obesity and metabolism
Changes in the Epidemiological Landscape of Diabetes in South Korea: Trends in Prevalence, Incidence, and Healthcare Expenditures: Kyoung Hwa Ha, Dae Jung Kim; Endocrinol Metab. 2024;39(5):669-677. Published online September 25, 2024; DOI: https://doi.org/10.3803/EnM.2024.2073

15,875 View
283 Download
10 Web of Science
13 Crossref

Abstract PDF Supplementary Material PubReader ePub

Diabetes is a serious public health concern that significantly contributes to the global burden of disease. In Korea, the prevalence of diabetes is 12.5% among individuals aged 19 and older, and 14.8% among individuals aged 30 and older as of 2022. The total number of people with diabetes among those aged 19 and older is estimated to be 5.4 million. The incidence of diabetes decreased from 8.1 per 1,000 persons in 2006 to 6.3 per 1,000 persons in 2014, before rising again to 7.5 per 1,000 persons in 2019. Meanwhile, the incidence of type 1 diabetes increased significantly, from 1.1 per 100,000 persons in 1995 to 4.8 per 100,000 persons in 2016, with the prevalence reaching 41.0 per 100,000 persons in 2017. Additionally, the prevalence of gestational diabetes saw a substantial rise from 4.1% in 2007 to 22.3% in 2023. These changes have resulted in increases in the total medical costs for diabetes, covering both outpatient and inpatient services. Therefore, effective diabetes prevention strategies are urgently needed.

Citations

Citations to this article as recorded by

Postpartum Glucose Intolerance in Women with a History of Gestational Diabetes Mellitus: An In-Depth Review
Kyung-Soo Kim, Soo-Kyung Kim, Yong-Wook Cho
Endocrinology and Metabolism.2026; 41(1): 26. CrossRef
Diabetes in Pregnancy in Korea: Prevalence, Clinical Characteristics, and Postpartum Comorbidities
Joon Ho Moon, Han Na Jung, Bongseong Kim, Seung-Hyun Ko, Soo Heon Kwak, Kyung-Do Han, Sung Hee Choi
Diabetes & Metabolism Journal.2026; 50(2): 280. CrossRef
Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
Kyoung Hwa Ha, Soyoung Shin, EunJi Na, Dae Jung Kim
Journal of Diabetes Investigation.2025; 16(2): 215. CrossRef
Effects of Black Cumin Seed Extract on Pancreatic Islet β-Cell Proliferation and Hypoglycemic Activity in Streptozotocin-Induced Diabetic Rats
Jongkyu Kim, Yoon-Seok Chun, Namkyu Yoon, Byungkwon Kim, Kiin Choi, Sae-Kwang Ku, Namju Lee
Antioxidants.2025; 14(2): 174. CrossRef
Older Adults with Diabetes in Korea: Latest Clinical and Epidemiologic Trends
Kyuho Kim, Bongseong Kim, Kyuna Lee, Yu-Bae Ahn, Seung-Hyun Ko, Sung Hee Choi, Kyungdo Han, Jae-Seung Yun
Diabetes & Metabolism Journal.2025; 49(2): 183. CrossRef
Elevated triglyceride-glucose index is a risk factor for cardiovascular events in adults with type 1 diabetes: a cohort study
Rosa Oh, Seohyun Kim, Sang Ho Park, Myunghwa Jang, So Hyun Cho, Ji Yoon Kim, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Gyuri Kim, Jae Hyeon Kim
Cardiovascular Diabetology.2025;[Epub] CrossRef
Association Between Healthy Dietary Patterns and Chronic Kidney Disease in Patients with Diabetes: Findings from Korean National Health and Nutrition Examination Survey 2019–2021
Minsang Kim, Jung Koh, Jeong Cho, Semin Cho, Soojin Lee, Hyuk Huh, Seong Kim, Sehyun Jung, Eunjeong Kang, Sehoon Park, Jin Paek, Woo Park, Kyubok Jin, Seungyeup Han, Kwon Joo, Kyungdo Han, Dong Kim, Yaerim Kim
Nutrients.2025; 17(9): 1600. CrossRef
Start Early, Do It Well: Implications of a National Diabetes Care Quality Assessment Program for Life Expectancy
Kyoung Hwa Ha, Dae Jung Kim
Diabetes & Metabolism Journal.2025; 49(5): 987. CrossRef
Bridging Evidence and Practice: A Consensus Statement from the Korean Diabetes Association on Diabetes Screening, Pharmacological Treatment and Severe Diabetes
Jong Han Choi, Shinae Kang, Soo-Kyung Kim, Won Jun Kim, Ji Min Kim, Jaehyun Bae, Jae-Seung Yun, Eonju Jeon, Young-Eun Kim, Jae Hyun Bae, Hun Jee Choe, Young Min Cho, Seung-Hyun Ko, Sang Yong Kim, Hae Jin Kim, You-Cheol Hwang, Min Kyong Moon, Suk Chon, Seo
Diabetes & Metabolism Journal.2025; 49(6): 1155. CrossRef
Pharmacoacupuncture for Lowering HbA1c in Korean Adult Patients With Hyperglycemia: A Retrospective Study
Ju-young Lee, Youngeun Yoo, Sanghun Lee
Acupuncture & Electro-Therapeutics Research: International Journal of Integrated Medicine.2025; 49(4): 230. CrossRef
Age-stratified comorbidity transitions and interconnected mapping of nine allergic diseases
Ju Hee Kim, Eun Lee, Jeewon Shin, Eunkyo Ha, Hana Yoo, Soonchul Lee, Man Yong Han
Allergology International.2025;[Epub] CrossRef
Association of diabetes, obesity, and their co-occurrence with suicide ideation in Korean adults using nationally representative data from 2019 to 2021
Shiva Raj Acharya, Sudarshan Subedi, Diwash Timilsina
Scientific Reports.2025;[Epub] CrossRef
Real-World Utility of GWAS-Based Diabetes Mellitus Panel Testing
In Hwa Jeong, Kyung-Won Hong, Ja-Eun Choi, Bo-Kyung Shine
International Journal of Molecular Sciences.2025; 27(1): 275. CrossRef

Adrenal gland
The Fascinating Interplay between Growth Hormone, Insulin-Like Growth Factor-1, and Insulin: Eline C. Nijenhuis-Noort, Kirsten A. Berk, Sebastian J. C. M. M. Neggers, Aart J. van der Lely; Endocrinol Metab. 2024;39(1):83-89. Published online January 9, 2024; DOI: https://doi.org/10.3803/EnM.2024.101

135,047 View
1,381 Download
38 Web of Science
42 Crossref

Abstract PDF PubReader ePub

This review intends to provide the reader with a practical overview of several (patho)physiological conditions in which knowledge of the interplay between growth hormone (GH), insulin-like growth factor-1 (IGF-1), and insulin is important. This might help treating physicians in making the right decisions on how to intervene and improve metabolism for the benefit of patients, and to understand why and how metabolism responds in their specific cases. We will specifically address the interplay between GH, IGF-1, and insulin in type 1 and 2 diabetes mellitus, liver cirrhosis, and acromegaly as examples in which this knowledge is truly necessary.

Citations

Citations to this article as recorded by

Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
Ruth Frampton, Samantha Hocking, Jennifer R. Snaith, Jerry R. Greenfield
Trends in Endocrinology & Metabolism.2026; 37(2): 135. CrossRef
Critical regulatory roles of non-coding RNAs in driving cancer sensitivity to Carmustine: a systematic review
Seyed Mostafa Rahimi, Abouzar Bagheri
Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(3): 3335. CrossRef
Zhi-Shen Pill ameliorates impaired glucose tolerance by targeting pancreatic β-cell and adipocyte pathways
Yinshan Huang, Xuan Ren, Xiudao Song, Kaiwen Xu, Lijuan Jin, Hui Zhu, Wei Chen, Wei Mu, Chunbo Jiang, Guoqiang Liang
Journal of Ethnopharmacology.2026; 357: 120931. CrossRef
Human growth hormone‐induced mitotic maladaptation in podocytes and implications in diabetic kidney disease
Bharath Banoth, Sumathi Raviraj, Anil Kumar Pasupulati
Journal of Neuroendocrinology.2026;[Epub] CrossRef
Dairy intake and risk of type 2 diabetes and metabolic syndrome: A narrative review
Karani Santhanakrishnan Vimaleswaran, Viswanathan Mohan
Nutrition.2026; 144: 113064. CrossRef
Maternal diet shapes milk bile acids to regulate neonatal growth through TGR5
Lufuno Phophi, Haley M. Wilt, Zhengzheng Hu, Rishi Gadikota, Mallory Cadiz, Mikayla S. Manzi, Freddie D. Ortiz Martinez, Sarayu Vanga, Elizabeth G. Chapman, Scott A. Tibbetts, Stephanie M. Karst
Cell Reports.2026; 45(1): 116744. CrossRef
Dietary Defective Jujube as a Corn Substitute: Impacts on Growth Performance, Meat Traits, and Alternaria Toxin Exposure in Lambs
Letian Zhang, Haoyang Hui, Muhammad Faheem, Yanfeng Xue, Ning Chen, Xiaoling Zhou
Animals.2026; 16(2): 255. CrossRef
Insulin Receptor Family Autoantibodies in Patients with Type B Insulin Resistance
Jennifer E Lee, Thilo S Chillon, Waldemar B Minich, Brent S Abel, Marissa Lightbourne, Lutz Schomburg, Rebecca J Brown
The Journal of Clinical Endocrinology & Metabolism.2026;[Epub] CrossRef
The relationship between IGF-1 and cardiovascular diseases and the potential mediating role of TyG-related index: evidence from a cohort study
Haipeng Chen, Ning Huang, Yang Huang, Jin Chen, Xu Luo
BMC Cardiovascular Disorders.2026;[Epub] CrossRef
IGF-1 as a mediator in the association between body mass index and risk of liver cancer: A prospective analysis of 432,203 participants from the UK biobank
Wenwen Yang, Zhixian Bao, Yuhua Chen, Jie Gao, Rui Ji
Growth Hormone & IGF Research.2026; 84: 101684. CrossRef
Associations of insulin-like growth factor 1 and IGF binding proteins 2 and 3 with lipids in toddlers
Johanna Neiß, Hans Demmelmair, Fabian Geyer, Alexander Triebswetter, Dudung Angkasa, Joaquin Escribano, Natalia Ferré, Mariona Gispert-Llauradó, Berthold Koletzko, Susanne Bechtold-Dalla Pozza, Veit Grote
Lipids in Health and Disease.2026;[Epub] CrossRef
Mechanisms in diabetes mellitus: Relationships to metabolism and/or neoplasia
John A. D'Elia, Bijan Roshan, Larry A. Weinrauch
Journal of Diabetes and its Complications.2026; 40(4): 109289. CrossRef
Corrigendum to ‘What type 1 diabetes endotype is most suitable for anti-CD3 antibodies prevention trials?’ [JDC, Vol. 39, Issue 10, October 2025, 109132]
Maria Aurora Roma-Wilson, Paolo Pozzilli
Journal of Diabetes and its Complications.2026; 40(3): 109230. CrossRef
Insulin-Like Growth Factor Signaling in Alzheimer’s Disease: Pathophysiology and Therapeutic Strategies
Jie Miao, Yanli Zhang, Chen Su, Qiandan Zheng, Junhong Guo
Molecular Neurobiology.2025; 62(3): 3195. CrossRef
GHRH in diabetes and metabolism
Charlotte Steenblock, Stefan R. Bornstein
Reviews in Endocrine and Metabolic Disorders.2025; 26(3): 413. CrossRef
Signaling pathways and targeted therapies in Ewing sarcoma
Ke Jia, Li Cao, Yihan Yu, Doudou Jing, Wei Wu, Brian Andrew Van Tine, Zengwu Shao
Pharmacology & Therapeutics.2025; 266: 108765. CrossRef
Expanding the Clinical and Mutational Spectrum of Biallelic POC1A Variants: Characterization of Four Patients and a Comprehensive Review of POC1A‐Related Phenotypes
Umut Altunoglu, Gozde Tutku Turgut, Esin Karakılıç Özturan, Tuğba Kalaycı, Mert Kaya, Güven Toksoy, Firdevs Baş, Hülya Kayserili, Feyza Darendeliler
Clinical Genetics.2025; 107(4): 390. CrossRef
Bridging Pubertal Changes and Endotype Based Therapy in Type 1 Diabetes
M. A. Roma‐Wilson, R. Buzzetti, S. Zampetti
Diabetes/Metabolism Research and Reviews.2025;[Epub] CrossRef
Training with electrical muscle stimulation: a novel method to improve Body Mass Index, lipid profile, growth hormone, and cortisol in overweight subjects
Elnaz RIYAHI, Jalil REISI, Sayyed M. MARANDI, Milad ABDOLLAHI
The Journal of Sports Medicine and Physical Fitness.2025;[Epub] CrossRef
Bilateral ovarian juvenile granulosa cell tumor in a neonate with Donohue syndrome: a case report and review of literature
Amany Reda Elbahbity, Amr Abdelhamid AbouZeid, Mohammad Hassan Mohamed, Mohammad Hassan Elibiary, Soha M. khafagy, Amira Mostafa Rashad, Shaimaa Mahmoud Abdelraouf, Sohair Abdelbaset Zayed, Manal Fawzy Gadalla, Shaimaa Abdelsattar Mohammad
Egyptian Pediatric Association Gazette.2025;[Epub] CrossRef
Association of IGF-1 and IGFBP-3 with metabolic abnormalities among children and adolescents
Zhenghao Zhao, Yuanyuan Ma, Xinyi Zhang, Xiaoxiao Liu, Yang Li, Zhongze Fang, Rongxiu Zheng, Jing Li
Frontiers in Endocrinology.2025;[Epub] CrossRef
Early Cardiovascular and Metabolic Benefits of rhGH Therapy in Adult Patients with Severe Growth Hormone Deficiency: Impact on Oxidative Stress Parameters
Maria Kościuszko, Angelika Buczyńska, Justyna Hryniewicka, Dorota Jankowska, Agnieszka Adamska, Katarzyna Siewko, Małgorzata Jacewicz-Święcka, Marcin Zaniuk, Adam Jacek Krętowski, Anna Popławska-Kita
International Journal of Molecular Sciences.2025; 26(12): 5434. CrossRef
Effects of warm-season feeding on yak growth, antioxidant capacity, immune function, and fecal microbiota
Yining Xie, Yangji Cidan, Zhuoma Cisang, Deji Gusang, Quzha Danzeng, Wangdui Basang, Yanbin Zhu, Jinshui Lin, Lizhuang Hao, Tariq Shah
Microbiology Spectrum.2025;[Epub] CrossRef
Post-Exercise Whey Protein Supplementation: Effects on IGF-1, Strength, and Body Composition in Pre-Menopausal Women, a Randomised Controlled Trial
Marc Murray, Lara Vlietstra, Alyssa M. D. Best, Stacy T. Sims, James A. Loehr, Nancy J. Rehrer
Nutrients.2025; 17(12): 2033. CrossRef
Diagnostic accuracy of triglyceride to glucose index and triglyceride/high-density lipoprotein index for insulin resistance among children and adolescents: A systematic review
Miguel Cabanillas-Lazo, Carlos Quispe-Vicuña, Milagros Pascual-Guevara, Claudia Cruzalegui-Bazán, Arturo Duran-Pecho, José Paz-Ibarra, Victor Velásquez-Rimachi, Qian Wu
PLOS One.2025; 20(6): e0326179. CrossRef
Diabetes and Bone Health: A Comprehensive Review of Impacts and Mechanisms
Prabhat Upadhyay, Sudhir Kumar
Diabetes/Metabolism Research and Reviews.2025;[Epub] CrossRef
High Blood Lead Levels as A Risk Factor of Stunting: A Study of Children in Agricultural Areas
Alfan Afandi, Suhartono Suhartono, Budiyono Budiyono, Ani Margawati, Apoina Kartini
JURNAL KESEHATAN LINGKUNGAN .2025; 17(1): 45. CrossRef
Viral Infections in Type 2 Diabetes: A Dangerous Liaison
Azizul Haque, Anudeep B. Pant
Viruses.2025; 17(9): 1150. CrossRef
Intranasal nanoparticle therapy for arsenic-induced neurotoxicity: Restoring IGF-1 signaling and advancing translational neuroprotection
Nourhan Elsayed, Jhi Biau Foo
Neuroscience.2025; 585: 107. CrossRef
Serum IGF-1 May be less reliable when assessing the GH-IGF-1 axis in the elderly
Angelo Milioto, Gudmundur Johannsson, Daniela Esposito
Pituitary.2025;[Epub] CrossRef
Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease
Ralf Weiskirchen, Amedeo Lonardo
International Journal of Molecular Sciences.2025; 26(19): 9594. CrossRef
Regenerative therapeutic effects of conditioned medium from human umbilical cord‑derived mesenchymal stem cells as an adjuvant to insulin therapy in a rat model of type 2 diabetes
Siufui Hendrawan, Jennifer Lheman, Olivia Marcelina, Lydia Tantoso, Hans Baer, Shirly Gunawan
World Academy of Sciences Journal.2025; 7(6): 1. CrossRef
Prevalence of Liver Steatosis and Fibrosis Assessed by Transient Elastography in a High Cardiovascular-Risk Outpatient Cohort Including T1DM and T2DM Patients
Alina N. Saidi, Willy B. Theel, Diederick E. Grobbee, Aart-Jan van der Lely, Femme Dirksmeier-Harinck, Marco Alings, Ellen van der Zwan-van Beek, Simone P. Rauh, Moniba Rasheed, Manuel Castro Cabezas
Diabetology.2025; 6(11): 129. CrossRef
Interconnected Mechanistic Pathways, Molecular Biomarkers, and Therapeutic Approach of Oral Cancer in Patients with Diabetes Mellitus
Viviana Elian, Violeta Popovici, Mihnea Ioan Nicolescu, Alexandra Maria Nicolescu, Sorina Maria Aurelian, Emma Adriana Ozon
Current Issues in Molecular Biology.2025; 47(11): 929. CrossRef
Adverse events with usage of human growth hormone: a review
Ludwik K. Branski, Sarita Thanedar, Nafis Deen, Kevin W. Cho, Gongkai Liu, Gabriel Hundeshagen, David N. Herndon, Linda E. Sousse
Discover Medicine.2025;[Epub] CrossRef
Unlocking Gut-Driven Metabolic Repair: The Role of Glucomannan Porang (Amorphophallus muelleri Blume) in Insulin Resistance and Short-Chain Fatty Acid Modulation in a Type 2 Diabetes Mellitus Rat Model
Azizah H. Safitri, Rahmata A. Sayyida, Eni Widayati, Nurina Tyagita
Tropical Journal of Natural Product Research.2025;[Epub] CrossRef
Effects of Short-Term (20-Day) Alternate-Day Modified Fasting and Time-Restricted Feeding on Fasting Glucose and IGF-1 in Obese Young Women
Dian Aristia Rachmayanti, Purwo Sri Rejeki, Raden Argarini, Hermina Novida, Sri Soenarti, Shariff Halim, Chy’as Diuranil Astrid Permataputri, Sheeny Priska Purnomo
Diseases.2025; 13(12): 390. CrossRef
Human Cancers Derived from Either Genetic or Lifestyle Factors Are Initiated by Impaired Estrogen Signaling
Zsuzsanna Suba
Cancers.2025; 18(1): 78. CrossRef
IGF-1 and IGF-2 as Molecules Linked to Causes and Consequences of Obesity from Fetal Life to Adulthood: A Systematic Review
Justyna Szydlowska-Gladysz, Adrianna Edyta Gorecka, Julia Stepien, Izabela Rysz, Iwona Ben-Skowronek
International Journal of Molecular Sciences.2024; 25(7): 3966. CrossRef
Insulin resistance reduction, intermittent fasting, and human growth hormone: secondary analysis of a randomized trial
Benjamin D. Horne, Jeffrey L. Anderson, Heidi T. May, Tami L. Bair, Viet T. Le, Leslie Iverson, Kirk U. Knowlton, Joseph B. Muhlestein
npj Metabolic Health and Disease.2024;[Epub] CrossRef
Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin
Kevin C. J. Yuen, Rikke Hjortebjerg, Ashok Ainkaran Ganeshalingam, David R. Clemmons, Jan Frystyk
Frontiers in Endocrinology.2024;[Epub] CrossRef
Comprehensive Management of Diabetes Mellitus in the Elderly: A Review
Bharat Kumar, Ravi Kant, Gopal Krishana Bohra
Journal of Cardio-diabetes and Metabolic Disorders.2023; 3(2): 21. CrossRef

Diabetes, obesity and metabolism
The Benefits Of Continuous Glucose Monitoring In Pregnancy: Jee Hee Yoo, Jae Hyeon Kim; Endocrinol Metab. 2023;38(5):472-481. Published online October 11, 2023; DOI: https://doi.org/10.3803/EnM.2023.1805

18,418 View
566 Download
12 Web of Science
14 Crossref

Abstract PDF PubReader ePub

Previous studies have consistently demonstrated the positive effects of continuous glucose monitoring (CGM) on glycemic outcomes and complications of diabetes in people with type 1 diabetes. Guidelines now consider CGM to be an essential and cost-effective device for managing type 1 diabetes. As a result, insurance coverage for it is available. Evidence supporting CGM continues to grow and expand to broader populations, such as pregnant people with type 1 diabetes, people with type 2 diabetes treated only with basal insulin therapy, and even type 2 diabetes that does not require insulin treatment. However, despite the significant risk of hyperglycemia in pregnancy, which leads to complications in more than half of affected newborns, CGM indications and insurance coverage for those patients are unresolved. In this review article, we discuss the latest evidence for using CGM to offer glycemic control and reduce perinatal complications, along with its cost-effectiveness in pregestational type 1 and type 2 diabetes and gestational diabetes mellitus. In addition, we discuss future prospects for CGM coverage and indications based on this evidence.

Citations

Citations to this article as recorded by

The Use of Continuous Glucose Monitoring in Comparison to Self-Monitoring of Blood Glucose in Gestational Diabetes: A Systematic Review
Bhavadharini Balaji, Wesley Hannah, Polina V. Popova, Uma Ram, Mohan Deepa, Janeline Lunghar, Kumaran Uthra, Haritha Sagili, Sadishkumar Kamalanathan, Ranjit Mohan Anjana, Viswanathan Mohan
Journal of Diabetes Science and Technology.2026; 20(1): 173. CrossRef
Continuous glucose monitoring to improve pregnancy outcomes: a scoping review of the inclusion of persons of colour, minority and indigenous groups in research
Emily Gossen-Perez, Minglan Li, Elizabeth Lewis-Hills, Karaponi Okesene-Gafa, Charlotte Oyston
Discover Endocrinology and Metabolism.2026;[Epub] CrossRef
Glucose circadian rhythm assessment in pregnant women for gestational diabetes screening
Rafael Bravo, Kyung Hyun Lee, Sarah A. Nazeer, Jocelyn A. Cornthwaite, Michal Fishel Bartal, Claudia Pedroza
International Journal of Obesity.2025; 49(1): 118. CrossRef
Quality of Life in Women With Gestational Diabetes Mellitus and Treatment Satisfaction Upon Intermittently Scanned Continuous Glucose Monitoring
Sookyung Won, Hyeon Ji Kim, Jee Yoon Park, Kyung Joon Oh, Sung Hee Choi, Hak Chul Jang, Joon Ho Moon
Journal of Korean Medical Science.2025;[Epub] CrossRef
Glucose time in range trajectories during pregnancy and association with adverse perinatal outcomes: a joint latent-class trajectory modeling approach
Sara M. Sauer, Isabel Fulcher, Ayodeji Sanusi, Ashley N. Battarbee
American Journal of Obstetrics & Gynecology MFM.2025; 7(6): 101669. CrossRef
Addressing the Diabetes Tsunami Requires Expanded Access to Diabetes Technologies
Davida F. Kruger, Christopher G. Parkin, Irl B. Hirsch, Grazia Aleppo, Janet B. McGill, Rodolfo J. Galindo, Carol J. Levy, Guillermo E. Umpierrez, George Grunberger, Richard M. Bergenstal
Journal of Diabetes Science and Technology.2025;[Epub] CrossRef
Prise de position d’un groupe d’experts – utilisation de la mesure en continu du glucose chez les patients vivant avec un diabète de type 2 en France
Michael Joubert, Benjamin Bouillet, Gaëtan Prevost, Bruno Vermesse, Helen Mosnier-Pudar, Jean-François Thébaut, Jean-Pierre Riveline, Noëlle Davoust, Bruno Guerci, Laurent Meyer
Médecine des Maladies Métaboliques.2025; 19(4): 331. CrossRef
Continuous glucose monitoring system in diabetes in pregnancy: a narrative review
Melanie Rodacki, Marcio Krakauer, Denise Reis Franco, Patricia Medici Dualib, Mauro Sancovski, Lenita Zajdenverg
Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Case Studies From India: Management of Diabetes Using Continuous Glucose Monitoring
Ajay Kumar Gupta, Ajay Krishnan, Manu Kataria, Nishesh Jain
Cureus.2025;[Epub] CrossRef
Experiences of Women With Diabetes Using Wearable Continuous Glucose Monitors During Pregnancy: A Qualitative Descriptive Study
Hee Sun Kang, Hyang Rang Park, Jangmi Kang, Chun-Ja Kim
The Science of Diabetes Self-Management and Care.2025; 51(6): 559. CrossRef
Neonatal Outcomes and A1C Improved With Real-Time Continuous Glucose Monitoring in Pregnancy With Preexisting Type 2 Diabetes
Gail L. Nunlee-Bland, Rochanda Mitchell, Inez V. Reeves, Michal A. Young
Diabetes Spectrum.2025; 38(4): 461. CrossRef
Dispositivi indossabili per la gestione del diabete
Filippo CARLUCCI, Antonella TABUCCHI, Marcello FIORINI, Lucrezia GALASSO, Alessandro TERRENI
Biochimica Clinica.2025;[Epub] CrossRef
Wearable devices for glucose monitoring: A review of state-of-the-art technologies and emerging trends
Mohammad Mansour, M. Saeed Darweesh, Ahmed Soltan
Alexandria Engineering Journal.2024; 89: 224. CrossRef
Diagnosis and Treatment of Hyperglycemia in Pregnancy
Sneha Mohan, Aoife M. Egan
Endocrinology and Metabolism Clinics of North America.2024; 53(3): 335. CrossRef

Original Article

Diabetes, Obesity and Metabolism
Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors: Hidefumi Inaba, Yosuke Kaido, Saya Ito, Tomonao Hirobata, Gen Inoue, Takakazu Sugita, Yuki Yamamoto, Masatoshi Jinnin, Hiroaki Kimura, Tomoko Kobayashi, Shintaro Iwama, Hiroshi Arima, Takaaki Matsuoka; Endocrinol Metab. 2022;37(1):84-95. Published online February 28, 2022; DOI: https://doi.org/10.3803/EnM.2021.1282

9,912 View
205 Download
27 Web of Science
27 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Type 1 diabetes mellitus induced by immune-checkpoint inhibitors (ICI-T1DM) is a rare critical entity. However, the etiology of ICI-T1DM remains unclear.
Methods
In order to elucidate risk factors for ICI-T1DM, we evaluated the clinical course and immunological status of patients with ICI-T1DM who had been diagnosed during 2016 to 2021.
Results
Seven of 871 (0.8%, six men and one woman) patients developed ICI-T1DM. We revealed that the allele frequencies of human leukocyte antigen (HLA)-DPA1*02:02 and DPB1*05:01 were significantly higher in the patients with ICI-T1DM In comparison to the controls who received ICI (11/14 vs. 10/26, P=0.022; 11/14 vs. 7/26, P=0.0027, respectively). HLA-DRB1*04:05, which has been found to be a T1DM susceptibility allele in Asians, was also observed as a high-risk allele for ICI-T1DM. The significance of the HLA-DPB1*05:01 and DRB1*04:05 alleles was confirmed by an analysis of four additional patients. The absolute/relative neutrophil count, neutrophils-lymphocyte ratio, and neutrophil-eosinophil ratio increased, and the absolute lymphocyte count and absolute/relative eosinophil count decreased at the onset as compared with 6 weeks before. In two patients, alterations in cytokines and chemokines were found at the onset.
Conclusion
Novel high-risk HLA alleles and haplotypes were identified in ICI-T1DM, and peripheral blood factors may be utilized as biomarkers.

Citations

Citations to this article as recorded by

The evolving management of endocrine disorders induced by checkpoint inhibitors: insights from the CIITED group
Priyanka C. Iyer, Nupur Kikani, Sonya Khan, Aysha Chaudhri, Gabriel Pagnotti, Conor Best, Steven Weitzman, Paras Mehta, Victor Lavis, Sonali Thosani, Ayush Gandhi, Rebecca Schneider Aguirre, Jeena Varghese, Theresa Guise, Ramona Dadu
Expert Review of Endocrinology & Metabolism.2026; 21(1): 29. CrossRef
Immune checkpoint inhibitor‐related type 1 diabetes incidence, risk, and survival association
Fumika Kamitani, Yuichi Nishioka, Miyuki Koizumi, Hiroki Nakajima, Yukako Kurematsu, Sadanori Okada, Shinichiro Kubo, Tomoya Myojin, Tatsuya Noda, Tomoaki Imamura, Yutaka Takahashi
Journal of Diabetes Investigation.2025; 16(2): 334. CrossRef
Immune checkpoint inhibitor-related diabetes mellitus associated with high signal intensity in diffusion-weighted magnetic resonance imaging of the pancreas at an early clinical stage
Masaki Suzuki, Yushi Hirota, Shin Urai, Masaaki Yamamoto, Keitaro Sofue, Wataru Ogawa
Hormones.2025; 24(2): 569. CrossRef
Durvalumab-induced Type 1 Diabetes in a Patient With Pre-existing GADA-positive Diabetes and Preserved Insulin Secretion
Nobuhiro Nakatake, Megumi Matsuda, Hiroki Kontani
JCEM Case Reports.2025;[Epub] CrossRef
Machine-Learning Parsimonious Prediction Model for Diagnostic Screening of Severe Hematological Adverse Events in Cancer Patients Treated with PD-1/PD-L1 Inhibitors: Retrospective Observational Study by Using the Common Data Model
Seok Jun Park, Seungwon Yang, Suhyun Lee, Sung Hwan Joo, Taemin Park, Dong Hyun Kim, Hyeonji Kim, Soyun Park, Jung-Tae Kim, Won Gun Kwack, Sung Wook Kang, Yun-Kyoung Song, Jae Myung Cha, Sang Youl Rhee, Eun Kyoung Chung
Diagnostics.2025; 15(2): 226. CrossRef
Risk Factors Associated with the Development of Immune-Checkpoint Inhibitor Diabetes Mellitus: An Integrative Review
Vivian Crowder, Veronica Brady
Life.2025; 15(7): 1063. CrossRef
Checkpoint Inhibitor-Associated Diabetes Mellitus Following Rapid Pancreatic Metastasis Resolution: Implications for Endocrine Toxicities in Immunotherapy
Sinead Cadogan, Sadhbh Doherty, Deirdre Kelly, Nigel Glynn
AACE Endocrinology and Diabetes.2025; 12(4): 339. CrossRef
Immune-Related Adverse Events of Checkpoint Inhibitors and Human Leukocyte Antigen System: A Review
Kamil Kośmider, Agata Kozakiewicz, Paweł Krawczyk, Robert Kieszko, Katarzyna Szklener, Magdalena Skórzewska, Kamila Wojas-Krawczyk, Ewa Kalinka, Janusz Milanowski
ImmunoTargets and Therapy.2025; Volume 14: 1455. CrossRef
Type 1 diabetes mellitus affected by potential toxicity from long-term use of nivolumab
Yuma Motomura, Shin Urai, Yushi Hirota, Naoki Takegawa, Hironori Bando, Masaaki Yamamoto, Hidenori Fukuoka, Masahiro Tsuda, Wataru Ogawa
Diabetology International.2024; 15(1): 130. CrossRef
Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors
Karlijn de Joode, Niels Heersche, Edwin A. Basak, Sander Bins, Astrid A.M. van der Veldt, Ron H.N. van Schaik, Ron H.J. Mathijssen
Cancer Treatment Reviews.2024; 122: 102662. CrossRef
Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes
Shunya Yabuki, Hiroyuki Hirai, Chihiro Moriya, Yoshiro Kusano, Takeo Hasegawa
Frontiers in Endocrinology.2024;[Epub] CrossRef
Reaching the Diagnosis of Checkpoint Inhibitor-Induced Diabetes Mellitus in Different Clinical Scenarios: A Real-World Application of Updated Diagnostic Criteria
Anna Angelousi, Dimitrios C. Ziogas, Vasiliki Siampanopoulou, Chrysoula Mytareli, Amalia Anastasopoulou, George Lyrarakis, Helen Gogas
Diseases.2024; 12(2): 40. CrossRef
Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
Ben Ponvilawan, Abdul Wali Khan, Janakiraman Subramanian, Dhruv Bansal
Cancers.2024; 16(6): 1225. CrossRef
A case of rapidly progressive insulin-dependent diabetes mellitus without islet autoantibodies developed over two years after the first dose of nivolumab
Kota Nishihama, Yuko Okano, Chisa Inoue, Kanako Maki, Kazuhito Eguchi, Soichiro Tanaka, Atsuro Takeshita, Mei Uemura, Taro Yasuma, Toshinari Suzuki, Esteban C. Gabazza, Yutaka Yano
Diabetology International.2024; 15(3): 583. CrossRef
HLA investigation in ICI-induced T1D and isolated ACTH deficiency including meta-analysis
Mayo Ono, Mototsugu Nagao, Haruki Takeuchi, Etsuya Fukunaga, Tomoko Nagamine, Kyoko Inagaki, Izumi Fukuda, Masato Iwabu
European Journal of Endocrinology.2024; 191(1): 9. CrossRef
Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus
Eleni-Rafaela Kani, Eleftheria Karaviti, Dimitra Karaviti, Eleni Gerontiti, Ioanna A. Paschou, Katerina Saltiki, Katerina Stefanaki, Theodora Psaltopoulou, Stavroula A. Paschou
Endocrine.2024; 87(3): 875. CrossRef
A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome
John Marsiglio, Jordan P. McPherson, Magdalena Kovacsovics-Bankowski, Joanne Jeter, Christos Vaklavas, Umang Swami, Douglas Grossmann, Alyssa Erickson-Wayman, Heloisa P. Soares, Katie Kerrigan, Berit Gibson, Jennifer Anne Doherty, John Hyngstrom, Sheetal
Frontiers in Immunology.2023;[Epub] CrossRef
Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment
Almog Shalit, Panagiotis Sarantis, Evangelos Koustas, Eleni-Myrto Trifylli, Dimitris Matthaios, Michalis V. Karamouzis
Cancers.2023; 15(2): 375. CrossRef
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
Iñigo Les, Mireia Martínez, Inés Pérez-Francisco, María Cabero, Lucía Teijeira, Virginia Arrazubi, Nuria Torrego, Ana Campillo-Calatayud, Iñaki Elejalde, Grazyna Kochan, David Escors
Cancers.2023; 15(5): 1629. CrossRef
Amino acid polymorphisms in human histocompatibility leukocyte antigen class II and proinsulin epitope have impacts on type 1 diabetes mellitus induced by immune-checkpoint inhibitors
Hidefumi Inaba, Shuhei Morita, Daisuke Kosugi, Yuki Asai, Yosuke Kaido, Saya Ito, Tomonao Hirobata, Gen Inoue, Yuki Yamamoto, Masatoshi Jinnin, Hiroaki Kimura, Masao Ota, Yuko Okudaira, Hiroyasu Nakatani, Tomoko Kobayashi, Shintaro Iwama, Hiroshi Arima, T
Frontiers in Immunology.2023;[Epub] CrossRef
Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study
Natsuko Hara, Hirotsugu Suwanai, Fumiyoshi Yakou, Keitaro Ishii, Hajime Iwasaki, Hironori Abe, Jumpei Shikuma, Hiroyuki Sakai, Takashi Miwa, Ryo Suzuki
Endocrine.2023; 81(3): 477. CrossRef
Autoimmunity in immune checkpoint inhibitor‐induced immune‐related adverse events: A focus on autoimmune skin toxicity and pneumonitis
Fiamma Berner, Lukas Flatz
Immunological Reviews.2023; 318(1): 37. CrossRef
Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland
Ichiro Yamauchi, Takuro Hakata, Taku Sugawa, Daisuke Kosugi, Haruka Fujita, Kentaro Okamoto, Yohei Ueda, Toshihito Fujii, Daisuke Taura, Norio Harada, Nobuya Inagaki
Endocrine Journal.2023; 70(10): 987. CrossRef
Key Determinants of Immune-Mediated Adverse Reactions to Oncology Drugs
Yihan Zhou, Shan Ding
Cancers.2023; 15(23): 5622. CrossRef
Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer
Majd Issa, Joy Tang, Yizhen Guo, Chris Coss, Thomas A. Mace, Jason Bischof, Mitch Phelps, Carolyn J Presley, Dwight H Owen
Expert Review of Anticancer Therapy.2022; 22(8): 861. CrossRef
Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
Adithya Chennamadhavuni, Laith Abushahin, Ning Jin, Carolyn J. Presley, Ashish Manne
Frontiers in Immunology.2022;[Epub] CrossRef
Flash Glucose Monitoring and Diabetes Mellitus Induced by Immune Checkpoint Inhibitors: An Approach to Clinical Practice
Pablo Rodríguez de Vera-Gómez, Ana Piñar-Gutiérrez, Raquel Guerrero-Vázquez, Virginia Bellido, Cristóbal Morales-Portillo, María Pilar Sancho-Márquez, Pablo Espejo-García, Noelia Gros-Herguido, Gema López-Gallardo, María Asunción Martínez-Brocca, Alfonso
Journal of Diabetes Research.2022; 2022: 1. CrossRef

Brief Report

Diabetes, Obesity and Metabolism
Growth in Children with HLA-Conferred Susceptibility to Type 1 Diabetes: Liisa Saare, Aleksandr Peet, Vallo Tillmann; Endocrinol Metab. 2022;37(1):175-179. Published online February 28, 2022; DOI: https://doi.org/10.3803/EnM.2021.1262

5,019 View
105 Download

Abstract PDF PubReader ePub: The incidence of type 1 diabetes (T1D) is increasing throughout the world. This trend may be explained by the accelerator hypothesis. Our study investigated growth, its biochemical markers, and their associations with the development of diabetes-associated autoantibodies (DAAB) in 219 children with genetic risk for T1D. Subjects were divided into risk groups based on their human leukocyte antigen genotype. Children in the moderate- to high-risk group were significantly taller when corrected to mid-parental height and had a lower insulin-like growth factor 1 (IGF-1)/IGF-1 binding protein (IGFBP-3) molar ratio than those in the low-risk group (corrected height standard deviation score 0.22±0.93 vs. –0.04±0.84, P<0.05; molar ratio 0.199±0.035 vs. 0.211+0.039, P<0.05). Children with DAAB tended to be taller and to have a higher body mass index than those with no DAAB. Our results suggest that the accelerator hypothesis explaining the increasing incidence of T1D may not solely be dependent on environmental factors, but could be partially genetically determined.

Review Articles

Miscellaneous
Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors: Shintaro Iwama, Tomoko Kobayashi, Hiroshi Arima; Endocrinol Metab. 2021;36(2):312-321. Published online April 27, 2021; DOI: https://doi.org/10.3803/EnM.2021.1007

10,945 View
325 Download
29 Web of Science
27 Crossref

Abstract PDF PubReader ePub

Immune-related adverse events (irAEs) affecting the endocrine glands are among the most frequent irAEs induced by immune checkpoint inhibitors (ICIs) and include hypopituitarism, primary adrenal insufficiency, thyrotoxicosis, hypothyroidism, hypoparathyroidism, and type 1 diabetes mellitus. Since the incidence and clinical features of endocrine irAEs vary according to the ICI used, it is important to understand the characteristics of these irAEs and to manage each one appropriately. Since some endocrine irAEs, including adrenal crisis and diabetic ketoacidosis, are potentially life-threatening, predicting the risk of endocrine irAEs before their onset is critical. Several autoantibodies have been detected in patients who develop endocrine irAEs, among which anti-thyroid antibodies may be predictive biomarkers of thyroid dysfunction. In this review, we describe the clinical features of each endocrine irAE induced by ICIs and discuss their potential biomarkers, including autoantibodies.

Citations

Citations to this article as recorded by

Blood glucose variability in early-onset adrenocorticotropic hormone deficiency induced by immune checkpoint inhibitor therapy with continuous blood glucose monitoring: a case report
Yuta Nanao, Gentaro Egusa, Ryuta Baba, Takaya Kodama, Tsuguka Matsuda, Gaku Nagano, Haruya Ohno
Diabetology International.2026;[Epub] CrossRef
Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors
Shintaro Iwama, Tomoko Kobayashi, Hiroshi Arima
Nature Reviews Endocrinology.2025; 21(5): 289. CrossRef
Thyroid Dysfunction After Intensity-Modulated Radiotherapy and PD⁃1 Inhibitor Treatment for Locally Advanced Nasopharyngeal Carcinoma
Kai Shang, Qianyong He, Xinyu Xu, Xunyan Luo, Chaofen Zhao, Lina Liu, Zhuoling Li, Yuanyuan Li, Feng Jin
Therapeutics and Clinical Risk Management.2025; Volume 21: 15. CrossRef
Subacute thyroiditis during anti-programmed cell death protein 1 antibody therapy: A case report
Makiko Ikemoto, Yasufumi Seki, Daisuke Watanabe, Toshio Takagi, Atsuhiro Ichihara
Thyroid Science.2025; 2(2): 100024. CrossRef
Combined PD-1 and CTLA-4 Blockade Increases the Risks of Multiple Pituitary Hormone Deficiency and Isolated Adrenocorticotropic Deficiency: A Prospective Study
Shintaro Iwama, Tomoko Kobayashi, Tetsushi Izuchi, Koji Suzuki, Takanori Murase, Masahiko Ando, Tomoko Handa, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tetsunari Hase, Shoichiro Mori, Tomoyasu Sano, Sh
Endocrinology and Metabolism.2025; 40(3): 459. CrossRef
Clinical characteristics and immunotherapy efficacy in advanced lung cancer patients with immune checkpoint inhibitor-related adrenal insufficiency
Lu Xu, Xinjie Zhang, Wang Yao, Vincent Kam Wai Wong
Medicine.2025; 104(34): e43983. CrossRef
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors
Ling Zhu, Yee-Ming M Cheung, Cherie Chiang, Emily J Gallagher, Ole-Petter R Hamnvik, Jennifer Mammen, Zoe Quandt, Renisha Jones, Jon McDunn, Huda Al-Bahadili, Trevor Angell, Irina Bancos, Allison Betof Warner, Susan Blackwell, Cassandra Calabrese, Tracey
Journal for ImmunoTherapy of Cancer.2025; 13(10): e011865. CrossRef
Increased risk of hyperthyroidism induced by immune checkpoint inhibitors in patients with existing or prior Graves’ disease: a nested prospective cohort study with propensity score matching
Koji Suzuki, Tomoko Kobayashi, Tetsushi Izuchi, Takanori Murase, Masahiko Ando, Tomoko Handa, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Hiroshi Arima, Shintaro Iwama
Frontiers in Endocrinology.2025;[Epub] CrossRef
Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events
Tomoko Kobayashi, Shintaro Iwama, Hiroshi Arima
Endocrine Journal.2024; 71(1): 23. CrossRef
A case of rapidly progressive insulin-dependent diabetes mellitus without islet autoantibodies developed over two years after the first dose of nivolumab
Kota Nishihama, Yuko Okano, Chisa Inoue, Kanako Maki, Kazuhito Eguchi, Soichiro Tanaka, Atsuro Takeshita, Mei Uemura, Taro Yasuma, Toshinari Suzuki, Esteban C. Gabazza, Yutaka Yano
Diabetology International.2024; 15(3): 583. CrossRef
Endocrinopathies Associated With Immune Checkpoint Inhibitor Use
Anupam Kotwal, Randol Kennedy, Nupur Kikani, Sonali Thosani, Whitney Goldner, Afreen Shariff
Endocrine Practice.2024; 30(6): 584. CrossRef
Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study
Tomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, Tetsushi Izuchi, Koji Suzuki, Koki Otake, Yoshinori Yasuda, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tetsunari Hase, Naoki Nishio, Shoi
Cancer Immunology, Immunotherapy.2024;[Epub] CrossRef
Adrenal Insufficiency and Thyrotoxicosis Following Combined Immune Checkpoint Inhibitor Use: A Case Report and Literature Review
Kaoruko Fukushima, Saori Kitayama, Manami Sazuka, Remi Kodera, Kazuhito Oba, Kenji Toyoshima, Yuko Chiba, Hiroshi Yamamoto, Atsushi Araki, Yoshiaki Tamura
Cureus.2024;[Epub] CrossRef
Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade
Ayana Yamagami, Shintaro Iwama, Tomoko Kobayashi, Xin Zhou, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Tetsushi Izuchi, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Hiroshi Arima
Endocrine Journal.2024; 71(5): 515. CrossRef
Single-cell RNA sequencing analysis of peripheral blood mononuclear cells in PD-1-induced renal toxicity in patients with lung cancer
Shusu Liu, Peiyu Lu, Bixia Yang, Yan Yang, Hua Zhou, Min Yang
BMC Nephrology.2024;[Epub] CrossRef
Development of pituitary dysfunction and destructive thyroiditis is associated with better survival in non-small cell lung cancer patients treated with programmed cell death-1 inhibitors: a prospective study with immortal time bias correction
Koji Suzuki, Tomoko Kobayashi, Tetsushi Izuchi, Koki Otake, Masahiko Ando, Tomoko Handa, Takashi Miyata, Mariko Sugiyama, Takeshi Onoue, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tetsunari Hase, Megumi Inoue, Makoto Ishii, Hiroshi Arima, Shintaro Iw
Frontiers in Endocrinology.2024;[Epub] CrossRef
Recovery from insulin dependence in immune checkpoint inhibitor‐associated diabetes mellitus: A case report
Marie Okubo, Yuji Hataya, Kanta Fujimoto, Toshio Iwakura, Naoki Matsuoka
Journal of Diabetes Investigation.2023; 14(1): 147. CrossRef
Case Report: A Rising Cause of New-Onset Endocrinopathies After Immunotherapy
Charity Tan, Sarah Hendricks, Kristina Hernandez, Martha Benavides, Rupinderjit Samra
The Journal for Nurse Practitioners.2023; 19(5): 104582. CrossRef
Risk of Thyroid Dysfunction in PD-1 Blockade Is Stratified by the Pattern of TgAb and TPOAb Positivity at Baseline
Xin Zhou, Shintaro Iwama, Tomoko Kobayashi, Masahiko Ando, Hiroshi Arima
The Journal of Clinical Endocrinology & Metabolism.2023; 108(10): e1056. CrossRef
Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
Liman Huo, Chao Wang, Haixia Ding, Xuelian Shi, Bin Shan, Ruoying Zhou, Ping Liang, Juan Hou
Frontiers in Oncology.2023;[Epub] CrossRef
Life-Threatening Endocrinological Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy
Aleksandra Basek, Grzegorz K. Jakubiak, Grzegorz Cieślar, Agata Stanek
Cancers.2023; 15(24): 5786. CrossRef
Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline
Shintaro Iwama, Tomoko Kobayashi, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Masahiko Ando, Xin Zhou, Ayana Yamagami, Takeshi Onoue, Yohei Kawaguchi, Takashi Miyata, Mariko Sugiyama, Hiroshi Takagi, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tets
The Journal of Clinical Endocrinology & Metabolism.2022; 107(4): e1620. CrossRef
Biomarkers and risk factors for the early prediction of immune-related adverse events: a review
Ying Zhang, Xiaoling Zhang, Weiling Li, Yunyi Du, Wenqing Hu, Jun Zhao
Human Vaccines & Immunotherapeutics.2022;[Epub] CrossRef
Immune Checkpoint Inhibitors as a Threat to the Hypothalamus–Pituitary Axis: A Completed Puzzle
Agnese Barnabei, Andrea Corsello, Rosa Maria Paragliola, Giovanni Maria Iannantuono, Luca Falzone, Salvatore Maria Corsello, Francesco Torino
Cancers.2022; 14(4): 1057. CrossRef
Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade
Tomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Xin Zhou, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tetsunari Hase, Masahiro Morise, Taka
The Journal of Clinical Endocrinology & Metabolism.2022; 107(10): e4115. CrossRef
Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors
Fabiana Pani, Yoshinori Yasuda, Sylvie T Rousseau, Kevin C Bermea, Solmaz Roshanmehr, Rulin Wang, Srinivasan Yegnasubramanian, Patrizio Caturegli, Luigi Adamo
Journal for ImmunoTherapy of Cancer.2022; 10(12): e005538. CrossRef
Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers
Anupam Kotwal, Mabel Ryder
Current Opinion in Endocrinology, Diabetes & Obesity.2021; 28(5): 517. CrossRef

Diabetes
Latent Autoimmune Diabetes in Adults: Current Status and New Horizons: Paolo Pozzilli, Silvia Pieralice; Endocrinol Metab. 2018;33(2):147-159. Published online June 21, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.2.147

26,498 View
589 Download
67 Web of Science
65 Crossref

Abstract PDF PubReader ePub

Autoimmune diabetes is a heterogeneous disease which can arise at any age. Subjects with adult-onset autoimmune diabetes who do not necessitate insulin-therapy for at least 6 months after diagnosis are demarcated as having latent autoimmune diabetes in adults (LADA). This condition is more heterogeneous than young-onset autoimmune diabetes and shares clinical and metabolic characteristics with both type 2 and type 1 diabetes. Patients with LADA are considered by having highly variable β-cell destruction, different degrees of insulin resistance and heterogeneous titre and pattern of islet autoantibody, suggesting different pathophysiological pathways partially explaining the heterogeneous phenotypes of LADA. To date the heterogeneity of LADA does not allow to establish a priori treatment algorithm and no specific guidelines for LADA therapy are available. These subjects are mostly treated as affected by type 2 diabetes, a factor that might lead to the progression to insulin-dependency quickly. A personalised medicine approach is necessary to attain optimal metabolic control and preserve β-cell function to decrease the risk of long-term diabetes complications. Recent data concerning the use of oral antidiabetic agents as dipeptidyl peptidase 4 inhibitors and glucagon-like peptide 1 receptor agonists indicate up-and-coming results in term of protect C-peptide levels and improving glycaemic control. This review summarises current knowledge on LADA, emphasising controversies regarding its pathophysiology and clinical features. Moreover, we discuss data available about novel therapeutic approaches that can be considered for prevention of β-cell loss in LADA.

Citations

Citations to this article as recorded by

Associations between perceived stress, psychosocial stressors, and HbA1c levels in healthy young adults from a prospective cohort study
Vivi Just-Nørregaard, Vita Ligaya Dalgaard, Jens M. Bruun, Johan Hviid Andersen, Trine Nøhr Winding
Scientific Reports.2026;[Epub] CrossRef
The prevalence of latent autoimmune diabetes misdiagnosed with type 2 diabetes mellites among adult patients in Jordan: A cross-sectional study
Rania Alwreikat, Lobna Gharaibeh, Munther S. Alnajjar
International Journal of Diabetes in Developing Countries.2026;[Epub] CrossRef
Characterization of Turner Syndrome-associated Diabetes Mellitus
Antoinette Cameron-Pimblett, Clementina La Rosa, Melanie C Davies, Jenifer P Suntharalingham, Miho Ishida, John C Achermann, Gerard S Conway
The Journal of Clinical Endocrinology & Metabolism.2025; 110(5): 1279. CrossRef
Latent Autoimmune Diabetes in Adults (LADA) Occurring in a Patient with Primary Biliary Cholangitis
Byung K. Lee, Kevin Pak, Paul J. Pockros
The American Journal of Medicine.2025; 138(1): 39. CrossRef
The potential of anti-glutamic acid decarboxylase antibodies to support a diagnosis of autoimmune diabetes mellitus
Maryah Liepert, Shamayel Alhaqqan, Alaa Husain, Heather Lochnan, Ronald A. Booth, Julie Shaw, Cathy J. Sun
Clinical Biochemistry.2025; 135: 110842. CrossRef
Slowly progressive subtype of childhood-onset type 1 diabetes as a high-risk factor for end-stage renal disease: A cohort study in Japan
Hiroshi Yokomichi, Mie Mochizuki, Shigeru Suzuki, Yoshiya Ito, Tomoyuki Hotsubo, Nobuo Matsuura
Journal of Diabetes and its Complications.2025; 39(1): 108922. CrossRef
Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults
Marco Infante, Francesca Silvestri, Nathalia Padilla, Francesca Pacifici, Donatella Pastore, Marcelo Maia Pinheiro, Massimiliano Caprio, Manfredi Tesauro, Andrea Fabbri, Giuseppe Novelli, Rodolfo Alejandro, Antonino De Lorenzo, Camillo Ricordi, David Dell
Journal of Clinical Medicine.2025; 14(4): 1303. CrossRef
Frequency of detection and factors of elevated levels of diabetes-associated autoantibodies in the blood of patients with clinical type 2 diabetes mellitus
Y.A. Saienko, B.M. Mankovsky
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2025; 21(2): 147. CrossRef
Recent advances in early diagnosis and treatment of T1D with miRNAs
Xinling Zhang, Yuting Qiu, Dong-ang Liu, Ruiyao Hu, Shiyu Chen, Yue Xu, Keyi Chen, Jinghua Yuan, Xiaoping Li
Frontiers in Endocrinology.2025;[Epub] CrossRef
LADA: The Evolving Landscape of Adult-Onset Autoimmune Diabetes
Maneeth Mylavarapu, Lakshmi Sravya Popuri, Niharika Tanwar, Ankur Singla, Fabeha Zafar, Dharma Rayaprolu, Yaswanth Kancharla, Diptish Wankhade, Sara Cherkos Dawit
SN Comprehensive Clinical Medicine.2025;[Epub] CrossRef
Renal hypouricemia type 2 in a patient with latent autoimmune diabetes in adults: a case report and literature review
Yunyi Cui, Hanyue Liu, Rui Dong
BMC Nephrology.2025;[Epub] CrossRef
Latent autoimmune diabetes in adults phenotype with recurrent hypoglycemia as diagnostic challenge (case report)
Teuta Mulla Goga, Afrim Zeqiraj
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2025; 21(8): 894. CrossRef
Diabetes in the African-Caribbean and the Romford Experience (DARE): A Retrospective Study
Noha Meneissy, Adnan Abdullah, Bhavini Bhatt, Ehsan Shakoor, Furhana Hussein, Zahid Khan, Lina Eltayieb, Bashir Mahamud, Azhar Faisymohammed, Gideon Mlawa
Cureus.2025;[Epub] CrossRef
Utility of Fasting C-Peptide for the Diagnostic Differentiation of Patients with Type 1, Type 2 Diabetes, MODY, and LADA
Ricardo Alemán-Contreras, Rita A. Gómez-Díaz, Maura E. Noyola-García, Rafael Mondragón-González, Niels Wacher, Aldo Ferreira-Hermosillo
Life.2024; 14(5): 550. CrossRef
Latent autoimmune diabetes in adults: current data (review of literature and own data)
N.V. Pashkovska, I.O. Tsaryk
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(3): 163. CrossRef
Dyslipidemia in latent autoimmune diabetes in adults: the relationship with vitamin D
I.O. Tsaryk, N.V. Pashkovska, V.I. Pankiv, V.M. Pashkovskyy
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(5): 357. CrossRef
Latent Autoimmune Diabetes in a Young Female: A Case Report
Keerthana K Pampapathi, Hsu Y Mon, Joshua M Ibrahim, Samson O Oyibo
Cureus.2024;[Epub] CrossRef
GLP-1 receptor agonist–induced diabetic ketoacidosis: A case report
Jiaming Zhang, Ying Ma, Qianhe Zu, Xiaohui Wang, Yao Zhang
Medicine.2024; 103(39): e39799. CrossRef
Global Trends in LADA Type Diabetes Research: A Bibliometric Analysis of Publications from Web of Science and Scopus, 1994–2024
Khatimya Kudabayeva, Bibigul Tleumagambetova, Yerlan Bazargaliyev, Raikul Kosmuratova, Aliya Zhylkybekova, Liping Yu
Journal of Diabetes Research.2024;[Epub] CrossRef
Vitamin D Supplementation as a Therapeutic Strategy in Autoimmune Diabetes: Insights and Implications for LADA Management
Niki G. Mourelatou, Dimitris Kounatidis, Edward B. Jude, Eleni Rebelos
Nutrients.2024; 16(23): 4072. CrossRef
Drug candidates and potential targets ofCurculigospp. compounds for treating diabetes mellitus based on network pharmacology, molecular docking and molecular dynamics simulation
Abdul Halim Umar, Diah Ratnadewi, Mohamad Rafi, Yohana Caecilia Sulistyaningsih, Hamim Hamim, Wisnu Ananta Kusuma
Journal of Biomolecular Structure and Dynamics.2023; 41(17): 8544. CrossRef
Development and validation of a clinical score for identifying patients with high risk of latent autoimmune adult diabetes (LADA): The LADA primary care-protocol study
Pilar Vich-Pérez, Juan Carlos Abánades-Herranz, Gustavo Mora-Navarro, Ángela María Carrasco-Sayalero, Miguel Ángel Salinero-Fort, Ignacio Sevilla-Machuca, Mar Sanz-Pascual, Cristina Álvarez Hernández-Cañizares, Carmen de Burgos-Lunar, Vijayaprakash Suppia
PLOS ONE.2023; 18(2): e0281657. CrossRef
Diagnostic Dilemmas and Current Treatment Approaches in Latent Onset Autoimmune Diabetes in Adults: A Concise Review
Lakshmi Chandran, Ankul Singh S., Chitra Vellapandian
Current Diabetes Reviews.2023;[Epub] CrossRef
Characteristics of adult-onset auto-immune type 1 diabetes
Faten Hadj Kacem, Ameni Jerbi, Bibi Twaheerah Allymamod, Wafa Bel Abed, Mouna Mnif, Nadia Charfi, Mouna Elleuch, Nabila Rekik, Hatem Masmoudi, Mohamed Abid
The American Journal of the Medical Sciences.2023; 366(1): 49. CrossRef
The role of cholecalciferol deficiency in the development of latent autoimmune diabetes in adults
I.O. Tsaryk, N.V. Pashkovska
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2023; 19(4): 259. CrossRef
Newly diagnosed type 1 diabetes mellitus in a human immunodeficiency virus-infected patient with antiretroviral therapy-induced immune reconstitution inflammatory syndrome: a case report
Min-ChunYeh, Han-Chuan Chuang, Shuen-Fu Weng, Chung-Huei Hsu, Chen-Ling Huang, Yu-Pei Lin, Yan-Yu Lin, Yu-Shan Hsieh
BMC Infectious Diseases.2023;[Epub] CrossRef
A Review on Latent Autoimmune Diabetes in Adults
Vijay Ravikumar, Ariba Ahmed, Ashish Anjankar
Cureus.2023;[Epub] CrossRef
Exploring Immune Therapies in a Twin Case of Latent Autoimmune Diabetes in Adults and Generalized Granuloma Annulare
Brian W. Connor, Sarah E.B. Smith, Andrea Kalus
Clinical Diabetes.2023; 41(4): 583. CrossRef
Innate immunity in latent autoimmune diabetes in adults
Juan Huang, James Alexander Pearson, F. Susan Wong, Li Wen, Zhiguang Zhou
Diabetes/Metabolism Research and Reviews.2022;[Epub] CrossRef
Endocrine Manifestations and New Developments in Mitochondrial Disease
Yi Shiau Ng, Albert Zishen Lim, Grigorios Panagiotou, Doug M Turnbull, Mark Walker
Endocrine Reviews.2022; 43(3): 583. CrossRef
Two Fifth-Generation Fighter Pilots Discovered with Latent Autoimmune Diabetes
Joe X. Zhang, Jacob Berry, Nathan M. Kim, Justin J. Gray, Savannah Fotheringham, Tom J. Sauerwein
Aerospace Medicine and Human Performance.2022; 93(2): 106. CrossRef
A Case of Late Diagnosis of Latent Autoimmune Diabetes in Adults
Joana R Costa, Ana Mestre, Mariana S Miranda, Frederica H Ferreira, Yahia Abuowda
Cureus.2022;[Epub] CrossRef
Class I MHC Polymorphisms Associated with Type 2 Diabetes in the Mexican Population
Paola Mendoza-Ramírez, Mildred Alejandra López-Olaiz, Adriana Lizeth Morales-Fernández, María Isabel Flores-Echiveste, Antonio de Jesus Casillas-Navarro, Marco Andrés Pérez-Rodríguez, Felipe de Jesús Orozco-Luna, Celso Cortés-Romero, Laura Yareni Zuñiga,
Genes.2022; 13(5): 772. CrossRef
Efficacy and safety of sitagliptin and insulin for latent autoimmune diabetes in adults: A systematic review and meta‐analysis
Tong Lin, Yinhe Cai, Liting Tang, Youwei Lian, Min Liu, Chaonan Liu
Journal of Diabetes Investigation.2022; 13(9): 1506. CrossRef
Partial Remission of Diabetes in a Young Adult While Testing Positive for Several Islet Cell Autoantibodies: A Case Report, Literature Review, and Patient Perspective
Samson O Oyibo
Cureus.2022;[Epub] CrossRef
Latent Autoimmune Diabetes in Adults and Metabolic Syndrome—A Mini Review
Niansi Pan, Shimei Yang, Xiaohong Niu
Frontiers in Endocrinology.2022;[Epub] CrossRef
Prevalence and factors associated with latent autoimmune diabetes in adults (LADA): a cross-sectional study
Anselmo M. Manisha, Aminiel R. Shangali, Sayoki G. Mfinanga, Erasto V. Mbugi
BMC Endocrine Disorders.2022;[Epub] CrossRef
Diabetic ketoacidosis as first presentation of latent autoimmune diabetes in adults in a patient with hashitoxicosis as first presentation of Hashimoto’s thyroiditis: a case report
Maria Xenou, Ioannis Zoupas, Dimitrios Lygnos, Evangelos Fousteris
Journal of Medical Case Reports.2022;[Epub] CrossRef
Latent Autoimmune Diabetes in Adults (LADA): From Immunopathogenesis to Immunotherapy
Jingyi Hu, Rong Zhang, Hailan Zou, Lingxiang Xie, Zhiguang Zhou, Yang Xiao
Frontiers in Endocrinology.2022;[Epub] CrossRef
Adult-onset autoimmune diabetes
Raffaella Buzzetti, Ernesto Maddaloni, Jason Gaglia, R. David Leslie, F. Susan Wong, Bernhard O. Boehm
Nature Reviews Disease Primers.2022;[Epub] CrossRef
Diagnostic camouflage: A case report on Latent autoimmune diabetics of adulthood
Sandhya kiran Neupane, Prakash Paudel Jaishi, Divyaa Koirala, Arjun Kandel, Prabhat Kiran Neupane
Annals of Medicine and Surgery.2022; 82: 104699. CrossRef
A Mechanistic Insight on Phytoconstituents Delivering Hypoglycemic Activity: A Comprehensive Overview
Shraddha Singh Raghav, Bhavna Kumar, Neeraj Kumar Sethiya, Ankur Kaul
Future Pharmacology.2022; 2(4): 511. CrossRef
Diagnostic Dilemmas in Young onset Diabetes Mellitus
Avijit Saha, Parna Roy
Annals of Medical Science & Research.2022; 1(3): 111. CrossRef
Prevalence of diabetes-associated autoantibodies among patients presenting with type 2 diabetes and related metabolic differences
Fatemeh Moosaie, Neda Meftah, Niloofar Deravi, Kosar Abouhamzeh, Fatemeh Dehghani Firouzabadi, Pegah Khaloo, Mohammad Ali Mansournia, Seyede Marzie Fatemi Abhari, Manouchehr Nakhjavani, Alireza Esteghamati
Primary Care Diabetes.2021; 15(1): 169. CrossRef
The association of human leukocyte antigen class II (HLA II) haplotypes with the risk of Latent autoimmune diabetes of adults (LADA): Evidence based on available data
Wenjun Chen, Xinlin Chen, Minting Zhang, Zunnan Huang
Gene.2021; 767: 145177. CrossRef
A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes
Thomas Forst, Pratik Choudhary, Doron Schneider, Bruno Linetzky, Paolo Pozzilli
Diabetes/Metabolism Research and Reviews.2021;[Epub] CrossRef
Bewusstseinsstörung, Tachypnoe und Tachykardie bei einem 71-jährigen Patienten mit Diabetes mellitus Typ 2
S. Großmann, U. Hoffmann, C. Girlich
Der Internist.2021; 62(6): 672. CrossRef
Good Glycemic Outcomes Following Bariatric Surgery Among Patients With Type 2 Diabetes, Obesity, and Low-Titer GAD Antibodies
Ruveena Kaur, David Kim, Richard Cutfield, Michael Booth, Lindsay Plank, Rinki Murphy
Diabetes Care.2021; 44(2): 607. CrossRef
Slowly evolving, immune-mediated diabetes in 14-year-old patient: a case report
M. R. Ragimov, D. D. Omelchuk, L. I. Ibragimova, O. S. Derevyanko, T. V. Nikonova
Diabetes mellitus.2021; 24(1): 70. CrossRef
Combination of vitamin D and dipeptidyl peptidase-4 inhibitors (VIDPP-4i) as an immunomodulation therapy for autoimmune diabetes
Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro, Susana Nogueira Diniz, Andrea Fabbri, Marco Infante
International Immunopharmacology.2021; 95: 107518. CrossRef
Current view of diagnosis and treatment of latent autoimmune diabetes in adults
Jana Urbanová, Ludmila Brunerová, Jana Malinovská, Barbora Pelechová, Ludmila Koberová, Jan Brož
Vnitřní lékařství.2021; 67(2): 97. CrossRef
Alpha‐amylase as molecular target for treatment of diabetes mellitus: A comprehensive review
Navjot Kaur, Vanktesh Kumar, Surendra Kumar Nayak, Pankaj Wadhwa, Paranjit Kaur, Sanjeev Kumar Sahu
Chemical Biology & Drug Design.2021; 98(4): 539. CrossRef
CLINICAL AND IMMUNOLOGICAL ASPECTS OF VERIFICATION OF LATENT AUTOIMMUNE DIABETES IN ADULTS AT EARLY STAGES OF DISEASE MANIFESTATION
Tetiana М. Tykhonova, Igor V. Belozоrov, Nadiya Ye. Barabash, Larysa O. Martymianova
Wiadomości Lekarskie.2021; 74(7): 1707. CrossRef
Bacillus Calmette-Guerin 's beneficial impact on glucose metabolism: Evidence for broad based applications
Gabriella F. Shpilsky, Hiroyuki Takahashi, Anna Aristarkhova, Michele Weil, Nathan Ng, Kacie J. Nelson, Amanda Lee, Hui Zheng, Willem M. Kühtreiber, Denise L. Faustman
iScience.2021; 24(10): 103150. CrossRef
Multicentre analysis of hyperglycaemic hyperosmolar state and diabetic ketoacidosis in type 1 and type 2 diabetes
S. R. Tittel, K. M. Sondern, M. Weyer, T. Poeplau, B. M. Sauer, M. Schebek, K.-H. Ludwig, F. Hammer, E. Fröhlich-Reiterer, R. W. Holl
Acta Diabetologica.2020; 57(10): 1245. CrossRef
Pancreas Pathology of Latent Autoimmune Diabetes in Adults (LADA) in Patients and in a LADA Rat Model Compared With Type 1 Diabetes
Anne Jörns, Dirk Wedekind, Joachim Jähne, Sigurd Lenzen
Diabetes.2020; 69(4): 624. CrossRef
Past, present and future of latent autoimmune diabetes in adults
Bingwen Liu, Yufei Xiang, Zhenqi Liu, Zhiguang Zhou
Diabetes/Metabolism Research and Reviews.2020;[Epub] CrossRef
Adult-onset autoimmune diabetes in 2020: An update
Ernesto Maddaloni, Chiara Moretti, Carmen Mignogna, Raffaella Buzzetti
Maturitas.2020; 137: 37. CrossRef
Altered peripheral nerve structure and function in latent autoimmune diabetes in adults
Tushar Issar, Aimy Yan, Natalie C. G. Kwai, Ann M. Poynten, Adeniyi A. Borire, Ria Arnold, Arun V. Krishnan
Diabetes/Metabolism Research and Reviews.2020;[Epub] CrossRef
Low rate of latent autoimmune diabetes in adults (LADA) in patients followed for type 2 diabetes: A single center’s experience in Turkey
Abbas Ali Tam, Didem Ozdemir, Nagihan Bestepe, Fatma Dilek Dellal, Muhammet Cuneyt Bilginer, Sevgul Faki, Cemile Bicer, Reyhan Ersoy, Bekir Cakir
Archives of Endocrinology and Metabolism.2020;[Epub] CrossRef
Distinguishing between type 1 and type 2 diabetes
Alexandra E Butler, David Misselbrook
BMJ.2020; : m2998. CrossRef
Exogenous Insulin Injection-Induced Stiff-Person Syndrome in a Patient With Latent Autoimmune Diabetes: A Case Report and Literature Review
Yi-Yin Lee, Cheng-Wei Lin, I-Wen Chen
Frontiers in Endocrinology.2020;[Epub] CrossRef
Investigating optimal β‐cell‐preserving treatment in latent autoimmune diabetes in adults: Results from a 21‐month randomized trial
Ingrid K. Hals, Hanne Fiskvik Fleiner, Nina Reimers, Marianne C. Astor, Karin Filipsson, Zuheng Ma, Valdemar Grill, Anneli Björklund
Diabetes, Obesity and Metabolism.2019; 21(10): 2219. CrossRef
Immunological and clinical characteristics of latent autoimmune diabetes in the elderly
Silvina Yohena, Alberto Penas‐Steinhardt, Clara Muller, Natalia I. Faccinetti, Gloria E. Cerrone, Silvia Lovecchio, Edgardo Ridner, Silvina Valdez, Gustavo Frechtel
Diabetes/Metabolism Research and Reviews.2019;[Epub] CrossRef
Autoimmunity in latent autoimmune diabetes in adults
Alessandro P. Delitala
AIMS Medical Science.2019; 6(2): 132. CrossRef

First
Prev
Page of 1
Next
Last

Search